Examination of the evidence for off-label use of gabapentin.
about
Reporting bias in medical research - a narrative reviewPublication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorderDid FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend AnalysisGabapentin misuse, abuse and diversion: a systematic reviewPossible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholismThe rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion.Myoclonus in renal failure: Two cases of gabapentin toxicityRisk of cancer in patients exposed to gabapentin in two electronic medical record systems.Prescribing gabapentin off label: Perspectives from psychiatry, pain and neurology specialists.Antiepileptic use for epilepsy and nonepilepsy disorders: A population-based study (1998-2013).Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysisHippocratic psychopharmacology for Bipolar Disorder-An Expert's Opinion.Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials.Development and validation of a new HPLC method for the determination of gabapentinGabapentin Modulates HCN4 Channel Voltage-Dependence.Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.New uses for older drugs: the tales of aspirin, thalidomide, and gabapentinRisk of respiratory depression with opioids and concomitant gabapentinoids.Utilization of gabapentin by people in treatment for substance use disorders in Belgium (2011-2014): a cross-sectional study.Reversible Thrombocytopenia after Gabapentin in an HIV-Positive Patient.Off-label prescribing of medications for pain: maintaining optimal care at an intersection of law, public policy, and ethicsGabapentin for Off-Label Use: Evidence-Based or Cause for Concern?Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance
P2860
Q21203744-11A575C0-3EDE-43D4-AA62-DFF3AD89D06DQ24643545-5048407E-C251-46FF-864C-8259B43AF807Q28551085-A5891E19-D181-42E8-AED7-83A08EB2F018Q30249803-DA8753CF-053F-44BB-A08C-F8F16A571401Q33548809-1A3DC3D0-3974-4448-97C3-A64914D8541AQ34617315-32E96F67-BD9E-4775-BC5D-2DE6B0818C98Q35018838-9DCF45B4-C20E-495D-9FB4-6015DC75CA80Q35858974-91FCD6D8-9ECD-4AB9-B447-C3D1C1CFA854Q36596045-53E234D9-C9FD-415A-8341-4F72A3C3D116Q36661735-35EEEFB6-372D-4810-9A57-AE0FE29C9E08Q37728271-36E67CD1-0329-45E9-837F-7C5E0C097947Q37813022-264F064D-26E9-4E3D-B5A8-CC8ADF9729BFQ38623830-278A580F-90A1-4614-86B0-E9324A19FF4DQ39529538-A5C6736A-AEF7-4BA3-A499-A8D50A46DB34Q41485000-1DCF29BB-6193-47E6-8A99-D613507AD5F1Q42369450-F4D00B96-11FA-4631-AF62-D78C9725C875Q42766204-C596A408-481D-4CFB-9A05-4BBA29A4A8B1Q46489342-54003267-48D6-4186-AA28-604A18E43FE7Q52645820-6AF54424-3473-47C5-B4A1-6FB97DB5A65BQ54256432-04D3A782-12E8-44F6-974A-BC5155FB32B1Q56774591-263A21EB-4CDF-4506-B0BB-A2B280CC518CQ58701953-0CD213A1-E11D-4DA6-B261-8E47A36CDF61Q58770131-50412A4E-7B7B-4A5B-B617-D4DCBD6AC1B9
P2860
Examination of the evidence for off-label use of gabapentin.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Examination of the evidence for off-label use of gabapentin.
@ast
Examination of the evidence for off-label use of gabapentin.
@en
Examination of the evidence for off-label use of gabapentin.
@nl
type
label
Examination of the evidence for off-label use of gabapentin.
@ast
Examination of the evidence for off-label use of gabapentin.
@en
Examination of the evidence for off-label use of gabapentin.
@nl
prefLabel
Examination of the evidence for off-label use of gabapentin.
@ast
Examination of the evidence for off-label use of gabapentin.
@en
Examination of the evidence for off-label use of gabapentin.
@nl
P1476
Examination of the evidence for off-label use of gabapentin.
@en
P2093
Alicia Mack
P304
P356
10.18553/JMCP.2003.9.6.559
P577
2003-11-01T00:00:00Z